China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter Phase II Clinical Trial of Sequential, Pulsed Administration of Teriflunomide, Decitabine and Lisaftoclax for Myelodysplastic Neoplasms with TP53 Multi-hit'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133952

Registration Time: 2026/10/09

Type: Interventional study

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=346598

Published by HT Digital Content Services with permission from Health Daily Digest....